Spring til hovednavigation Spring til søgning Spring til hovedindhold

Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies

    80 Citationer (Scopus)

    Abstract

    Treatment of Graves' disease (GD) with the B-lymphocyte depleting agent rituximab in addition to standard methimazole-therapy prolongs remission. Paradoxically, it does not mediate a reduction in thyrotropin receptor antibody (TRAb) levels over that of methimazole monotherapy. Using a bioassay involving Chinese hamster ovary cells transfected with the human thyrotropin receptor, we found that the stimulatory capacity of TRAbs was reduced markedly, by 66+/-22%, upon treatment with rituximab and methimazole for 21 days (p
    OriginalsprogEngelsk
    TidsskriftClinical Immunology
    Vol/bind130
    Udgave nummer3
    Sider (fra-til)252-8
    Antal sider7
    ISSN1521-6616
    DOI
    StatusUdgivet - 1 mar. 2009

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies'. Sammen danner de et unikt fingeraftryk.

    Citationsformater